Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT01273779 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT01273779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01273779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
Lead sponsor
Agennix
Phase
Phase 2/3
Overall status
Suspended
Start date
June 30, 2011
Completion date
December 31, 2014
Enrollment
1,280 (estimated)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

severe sepsis